Last reviewed · How we verify
NCT05782504: BC-PREHAB
Patient-centered Breast Cancer Teleprehabilitation
NA trial testing Patient-centered teleprehabilitation in Breast Cancer in 50 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Universitair Ziekenhuis Brussel |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 30 January 2023 |
| Primary completion | 30 June 2024 |
| Estimated completion | 31 August 2024 |
| Sites | 2 locations across Belgium |
Drugs / interventions tested
- Patient-centered teleprehabilitation
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Surgery — all drugs for Surgery →
Sponsor
Universitair Ziekenhuis Brussel — full company profile →
Who can join
18 and older, female only, with Breast Cancer or Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Surgery, the cornerstone of most cancer treatments, is associated with considerable postoperative complications. Adjusting patients' health behavior before surgery may have beneficial effects on postoperative outcomes. Women (n=50) who will undergo breast surgery because of stage I-III breast cancer are eligible. All participants will receive multimodal patient-centered teleprehabilitation comprising of motivational interviewing, education, exercise therapy, and stress management.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05782504
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Universitair Ziekenhuis Brussel trials
Trials by the same sponsor.
- NCT07536230 — Deep Learning Framework for Continuous Depth of Anesthesia Forecasting · not yet recruiting
- NCT07533968 — The Aim of This Study is to Gain Insight Into the Occurrence of Irritable Bowel Symptoms During Ovarian Stimulation in I · NA · not yet recruiting
- NCT07289984 — Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders and · NA · not yet recruiting
- NCT06923813 — Assessment of Nutrient Absorption in Enterally Fed Post-intensive Care Unit Patients Using Bomb Calorimetry: do the Calo · NA · recruiting
- NCT07401004 — Effect of Blink-Based Training on Cancer Detection in Colorectal Polyp Images by Medical Students/Non GI-trainees · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05782504 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitair Ziekenhuis Brussel
- Last refreshed: 23 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05782504.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing